What's New for MGH Inpatient Order Entry?

November 6, 2012—Kayexalate Decision Support

As of November 6th, providers ordering Kayexalate (polystyrene sulfonate) are warned of several potentially fatal contraindications against the administration of this drug.

Key features:

• Triggered by the selection of Kayexalate (polystyrene sulfonate) from medication search results

• Includes a link to current FDA safety information on Kayexalate

• Includes a link to the article on UpToDate on the treatment and prevention of hyperkalemia

• Lists absolute contraindications for Kayexalate (polystyrene sulfonate)

• Provides recommendations for alternative treatments

• If the provider does order Kayexalate, records all selections for patient safety and quality assurance monitoring

Instructions:

• Responding to the Kayexalate Warning

• Ordering Medications

See also:

• What’s new with the MGH eMAR?

• Archive of What's New for MGH Order Entry